Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Comparison of the intraocular pressure lowering efficacy between a trabecular meshwork micro-bypass device and a novel goniotomy blade

Poster Details

First Author: K.Mansouri SWITZERLAND

Co Author(s):                        

Abstract Details

Purpose:

To compare the intraocular pressure (IOP) lowering efficacy of cataract extraction (CE) combined with either trabecular meshwork microbypass device implantation (iStent, Glaukos, San Clemente, CA) versus goniotomy with the Kahook Dual Blade (KDB, New World Medical, Rancho Cucamonga, CA).

Setting:

Multi-center retrospective consecutive case series.

Methods:

A retrospective chart review was completed after securing institutional review board approval at each of seven different sites. Enrolled eyes suffered from mild to moderate glaucoma and underwent CE with either iStent implantation or KDB goniotomy. Data collected included demographic information, IOP, medication use and adverse events.

Results:

106 eyes and 58 eyes were enrolled in the CE+iStent and CE+KDB groups, respectively. Baseline data were similar between groups . In the CE + iStent group, baseline IOP was 16.6mmHg(SD 4.4), decreasing by 12% to 14.6mmHg (SD 3.2) at six month. In comparison, the CE + KDB baseline IOP was 16.8mmHg(SD 4.4), decreasing by 17% to 13.9mmHg(SD3.2). Medication usage in the CE+iStent group decreased 23% from 1.8 (SD 1.0) to 1.4 (SD 1.2) . In the CE+KDB group, medication usage decreased 39% from 1.9 (SD 1.0) to 1.1 (SD 1.2). Adverse events, similar between groups, were minor and self-limited.

Conclusions:

Combined CE+KDB resulted in numerically greater reduction in both IOP and dependence on IOP lowering medications when compared to CE+iStent. Further data collection is underway to compare the longer-term efficacy of these two approaches in patients with mild to moderate glaucoma undergoing CE.

Financial Disclosure:

NONE

Back to Poster listing